Five-year results of cervical total disc replacement (cTDR) compared with anterior discectomy and fusion (ACDF) to treat 2-level symptomatic degenerative disc disease: a prospective, randomized, controlled, multicenter investigational device exemption clinical trial have been published by the Journal of Neurosurgery: Spine. Study results indicated overall success rates at 5 years of 61% and 31% for the cTDR and ACDF groups, respectively.
While single-level long-term data have been published on the Pro-Disc-C (DePuy Synthes), Bryan and Prestige ST devices (latter two Medtronic), this paper represents the first report on 5-year Investigational Device Exemption data for 2-level cervical arthroplasty.
Christophe Lavigne, President and CEO of LDR, commented, “We believe that this publication will further support the movement among insurance payers to expand coverage to include two-level cervical disc replacement, allowing more surgeons and patients to benefit from the procedure.”
Sources: LDR Holding Corporation, Replacement compared with anterior discectomy and fusion for treatment of 2-level symptomatic degenerative disc disease: a prospective, randomized, controlled, multicenter investigational device exemption clinical trial, Published online March 25, 2016; DOI: 10.3171/2015.12.SPINE15824.
Five-year results of cervical total disc replacement (cTDR) compared with anterior discectomy and fusion (ACDF) to treat 2-level symptomatic degenerative disc disease: a prospective, randomized, controlled, multicenter investigational device exemption clinical trial have been published by the Journal of Neurosurgery: Spine. Study results...
Five-year results of cervical total disc replacement (cTDR) compared with anterior discectomy and fusion (ACDF) to treat 2-level symptomatic degenerative disc disease: a prospective, randomized, controlled, multicenter investigational device exemption clinical trial have been published by the Journal of Neurosurgery: Spine. Study results indicated overall success rates at 5 years of 61% and 31% for the cTDR and ACDF groups, respectively.
While single-level long-term data have been published on the Pro-Disc-C (DePuy Synthes), Bryan and Prestige ST devices (latter two Medtronic), this paper represents the first report on 5-year Investigational Device Exemption data for 2-level cervical arthroplasty.
Christophe Lavigne, President and CEO of LDR, commented, “We believe that this publication will further support the movement among insurance payers to expand coverage to include two-level cervical disc replacement, allowing more surgeons and patients to benefit from the procedure.”
Sources: LDR Holding Corporation, Replacement compared with anterior discectomy and fusion for treatment of 2-level symptomatic degenerative disc disease: a prospective, randomized, controlled, multicenter investigational device exemption clinical trial, Published online March 25, 2016; DOI: 10.3171/2015.12.SPINE15824.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.